 |
1-(4-(benzylamino)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-yl)-2-methyl-1H-indole-4-carboxamide |
|---|---|
| Trade Name | |
| Orphan Indication | Multiple myeloma |
| USA Market Approval | USA |
| USA Designation Date | 2015-07-08 00:00:00 |
| Sponsor | Cleave Biosciences, Inc.;866 Malcolm Road, Suite 100;Burlingame, California, 94010 |
Related Access Program
AbbVie – Multiple Myeloma
Janssen Research & Development, LLC – Multiple Myeloma
Dana-Farber Cancer Institute – Multiple Myeloma
Bristol-Myers Squibb – Multiple Myeloma
Peking University – Multiple Myeloma
Novartis Pharmaceuticals – Multiple Myeloma
Onyx Pharmaceuticals, Inc., an Amgen subsidiary – Multiple myeloma